Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS
Nantong, China – January 13, 2026 – Ractigen Therapeutics is pleased to announce that the…
RactigenJanuary 13, 2026
